- $16.19m
- -$40.86m
- $0.19m
aTyr Pharma's lung disease drug misses main goal in late-stage trial
Brief: aTyr Pharma Announces Topline Results From Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis
Brief: aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
aTyr Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
aTyr Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
aTyr Pharma Inc reports results for the quarter ended March 31 - Earnings Summary
aTyr Pharma Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: aTyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise
aTyr Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
aTyr Pharma Inc expected to post a loss of 23 cents a share - Earnings Preview
aTyr Pharma Inc reports results for the quarter ended in September 30 - Earnings Summary
aTyr Pharma Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Point72 Asset Management, L.P. Reports 6.2% Passive Stake In ATYR Pharma As Of Oct 14 - SEC Filing
aTyr Pharma Inc reports results for the quarter ended in June - Earnings Summary
aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview
aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview
aTyr Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview